首页 | 本学科首页   官方微博 | 高级检索  
检索        

华蟾素注射液治疗中晚期原发性肝癌临床疗效观察
引用本文:陈喆,翟笑枫,苏永华,万旭英,李瑾,谢觉民,高波.华蟾素注射液治疗中晚期原发性肝癌临床疗效观察[J].中西医结合学报,2003,1(3):184-186.
作者姓名:陈喆  翟笑枫  苏永华  万旭英  李瑾  谢觉民  高波
作者单位:1. 第二军医大学附属长海医院中医科,上海,200433
2. 安徽金蟾药业有限公司,安徽,淮北,235000
摘    要:目的 观察华蟾素注射液治疗中晚期原发性肝癌的临床疗效。方法  10 0例中晚期原发性肝癌患者随机分成华蟾素治疗组与一般治疗组 ,各 50例。分别观察两组患者治疗前后的生存质量、肿瘤大小、部分实验室指标的变化 ,并随访生存期。结果 在控制肿瘤方面 ,华蟾素治疗组的恶化率 (18% )低于一般治疗组 (3 2 % ) ;在生存质量方面 ,华蟾素治疗组的总有效率(80 % )高于一般治疗组 (72 % ) ,但两组比较无显著性差异 ;在生存期方面 ,华蟾素治疗组 >12个月的生存率 (3 0 % )显著高于一般治疗组 (18% ) ,两组比较有显著性差异 ;在肝功能方面 ,华蟾素治疗组的血清总胆红素、丙氨酸氨基转移酶等指标在治疗后有明显下降 ,而在一般治疗组则呈不同程度的升高 ;在甲胎蛋白 (AFP)方面 ,一般治疗组的AFP在治疗后较治疗前有明显上升 ,而华蟾素治疗组则略有上升 ,但与治疗前相比无显著性差异。结论 华蟾素注射液能在一定程度上抑制癌瘤的生长 ,并且具有保护肝功能、提高生存质量、延长生存期的作用 ,在治疗中晚期原发性肝癌方面 ,具有“攻邪不伤正”的特点

关 键 词:华蟾素注射液  治疗  中晚期  原发性肝癌  疗效观察
文章编号:1672-1977(2003)03-0184-03
修稿时间:2003年4月24日

Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer
CHEN Zhe ,ZHAI Xiao-Feng ,SU Yong-Hua ,WAN Xu-Ying ,LI Jin ,XIE Jue-Min ,GAO Bo.Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer[J].Journal of Chinese Integrative Medicine,2003,1(3):184-186.
Authors:CHEN Zhe  ZHAI Xiao-Feng  SU Yong-Hua  WAN Xu-Ying  LI Jin  XIE Jue-Min  GAO Bo
Institution:Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Abstract:OBJECTIVE: To observe the clinical effect of cinobufacini injection in treating moderate and advanced primary liver cancer (PLC). METHODS: One hundred patients with moderate and advanced PLC were randomly divided into cino-treated group (50 patients) and control group (50 patients). The quality of life, tumor size, some changes of laboratory tests, and survival time were observed. RESULTS: The progressive rate of cino-treated group (18%) was lower than that of the control group (32%). The quality of life of the cino-treated group (80%) was better than that of the control group (72%), but without statistical significance. The survival rate of >12 months of the cino-treated group (30%) was higher than that of the control group (18%). The patients' liver function such as serum total bilirubin and ALT decreased obviously in the cino-treated group while increased a lot in the control group. The level of AFP increased after treatment with statistical significance in the control group while there was no statistical significance in the cino-treated group. CONCLUSION: Cinobufacini injection can not only inhibit the proliferation of cancer, but also protect liver function, improve quality of life and prolong survival time.
Keywords:cinobufacini  therapy  carcinoma  hepatocytes
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号